Erasca Inc
Suletud
18.03 -7.54
Ülevaade
Aktsiahinna muutus
24h
Min
17.92
Max
19.48
Sissetulek | 139M -44M |
|---|---|
Aktsiakasum | -0.14 |
Töötajad | 103 |
EBITDA | 139M -43M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +23.81% upside |
Järgmine tulemuste avaldamine | 10. nov 2026 |
|---|
Turukapital | -134M 6.2B |
|---|---|
Eelmine avamishind | 25.57 |
Eelmine sulgemishind | 18.03 |
Erasca Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Erasca Inc Prognoos
Hinnasiht
By TipRanks
23.81% tõus
12 kuu keskmine prognoos
Keskmine 24.13 USD 23.81%
Kõrge 33 USD
Madal 20 USD
Põhineb 8 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.